BioHarvest Sciences (NasdaqGM:BHST) Update / Briefing September 10, 2025 01:00 PM ET Company ParticipantsIlan Sobel - CEOZaki Rakib - Chairman and President of CDMOConference Call ParticipantsNick Sherwood - AnalystRobert LeBoyer - AnalystHunter Diamond - AnalystMatt Hewitt - AnalystAlec Legg - AnalystOperatorGood day and welcome to the BioHarvest Sciences Virtual Investor Webinar. Today's webinar is being recorded. Before we begin the formal presentation, I'd like to remind everyone that statements made on ...

PresentationBrian SkorneySenior Research Analyst Good afternoon, everyone. Thank you so much for being here. Well, I guess it's not quite afternoon yet, but almost lunch time. So hang in there. I'm Brian Skorney. I'm one of Baird's senior biotech analysts. Really, really excited to have with us as the next fireside chat, Cindy Perettie. She's the CEO of Kite, a subsidiary of Gilead that works on cell therapy. Very interesting acquisition that the company made going almost a decade now ago, but it's a big pa ...

PresentationBrian SkorneySenior Research Analyst Good afternoon, everyone. Thank you so much for being here. Well, I guess it's not quite afternoon yet, but almost lunch time. So hang in there. I'm Brian Skorney. I'm one of Baird's senior biotech analysts. Really, really excited to have with us as the next fireside chat, Cindy Perettie. She's the CEO of Kite, a subsidiary of Gilead that works on cell therapy. Very interesting acquisition that the company made going almost a decade now ago, but it's a big pa ...

ProMIS Neurosciences (NasdaqCM:PMN) FY Conference September 10, 2025 12:30 PM ET Speaker0Good afternoon, everyone. Thank you for joining us for our next session at the H. C. Wainwright Global Investment Conference. My name is Joshua Corson, and I'm an equity research associate at H.C. Wainwright. For our next session, I would like to introduce our presenter, Neil Warmah, who is the CEO of Promis Neurosciences. Floor is yours.Speaker1Thanks very much. I appreciate it. Thanks everybody for joining this aftern ...

PresentationJudah FrommerEquity Analyst Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference. I'm Judah Frommer, one of the SMid biotech analysts here. Let me just read a quick disclosure before welcoming the Celldex team. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. With that, thank you, Celldex team f ...

PresentationJudah FrommerEquity Analyst Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference. I'm Judah Frommer, one of the SMid biotech analysts here. Let me just read a quick disclosure before welcoming the Celldex team. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. With that, thank you, Celldex team f ...

PresentationSo with that, I'd like to just congratulate you and the Insmed team on what's been an exceptional year so far. You secured FDA approval for Brinsupri, delivered impressive TPIP data and are building strong momentum going into year-end. With that, I'll open up the floor if you have any opening remarks.I'm Max Skor, a biotech analyst with Morgan Stanley, and I'm honored to have Will Lewis here, CEO of Insmed. Before we get started, though, I have to read some brief disclosures. For important discl ...

CorMedix (NasdaqGM:CRMD) FY Conference September 10, 2025 10:45 AM ET Company ParticipantsRoss Cohen - Executive DirectorJoe Todisco - CEORoss CohenOkay. Thank you all for joining. Just a quick note on disclosure. For important disclosures, please see the Morgan Stanley Research Disclosure website, or please reach out to your Morgan Stanley sales representatives for any disclosures. Welcome to the Morgan Stanley Healthcare Conference and the Fireside Chat with CorMedix. My name is Ross Cohen. I'm an Executi ...

PresentationSean LaamanHead of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. Smid-Cap Biotech Equity Research here at the firm. Before we commence, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Cullina ...

ORLANDO, FL / ACCESS Newswire / September 10, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company and innovator in exosome-based therapies, today announced a key strategic milestone towards expanding its commercial footprint and building significant shareholder value. The company has filed a new Provisional Patent (#63/877,517) that embodies a groundbreaking method for loading Extracellular Vesicles (EVs). ...